Umeclidinium is a long-acting muscarinic antagonist used as a long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than 80%.
- Mechanism
- Curator reviewed · 1 reference
Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of umeclidinium is predominantly a site-specific effect.
- Primary indication
- Umeclidinium is approved by the FDA and Health Canada for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).Curator reviewed · 8 structured indications
- Formula / weight
- C29H34NO2 · 428.595 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2014 · European Union, 2016
- Code names
- GSK-573719 · GSK573719A
- Brand names
Resolves to
FVTWTVQXNAJTQP-UHFFFAOYSA-NSMILESOC(C1=CC=CC=C1)(C1=CC=CC=C1)C12CC[N+](CCOCC3=CC=CC=C3)(CC1)CC2What you can answer from here — as of August 30, 2026
Which drugs share a target with Umeclidinium, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account